Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [111In]-labeled CHX-A''DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines

Malmberg,Jennie; Tolmachev,Vladimir; Orlova,Anna

doi:10.3892/etm.2011.217

Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [111In]-labeled CHX-A''DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines

Authors:
- Jennie Malmberg
- Vladimir Tolmachev
- Anna Orlova
View Affiliations

Affiliations: Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, S-751 85 Uppsala, Sweden
Published online on: February 22, 2011 https://doi.org/10.3892/etm.2011.217
Pages: 523-528

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The treatment of disseminated prostate cancer remains a great challenge in current oncology practice. The proliferation of prostate cancer cells is testosterone-driven, but clonal selection during androgen deprivation therapy promotes the development of androgen-independent (hormone-refractory) cells, which become phenotypically dominant. Human epidermal growth factor receptor type 2 (HER2) is capable of activating the androgen receptor pathway, even in the absence of the ligand. The detection of phenotypic changes associated with the development of androgen independence may influence patient management, suggesting the initiation of a second-line therapy. This study aimed to establish the level of HER2 expression in a number of prostate cancer cell lines (LNCaP, PC3 and DU145) in order that they be used as models in further studies, and to evaluate the binding and cellular processing of [111In]-labeled trastuzumab and the anti-HER2 synthetic Affibody molecule ABY-025 in these cell lines. The expression of HER2 was demonstrated and quantified in all three tested prostate cancer cell-lines. Studies on cellular processing demonstrated that internalization of both conjugates increased continuously during the whole incubation. The internalization rate was approximately equal for both monoclonal antibodies and Affibody molecules. In both cases, internalization was moderately rapid. Such features would definitely favor the use of radiometal labels for trastuzumab and, most likely, for affibody molecules. The level of HER2 expression in these cell lines is sufficient for in vivo molecular imaging.

View Figures

View References

1.	Taichman RS, Loberg RD, Mehra R and Pienta KJ: The evolving biology and treatment of prostate cancer. J Clin Invest. 117:2351–2361. 2007. View Article : Google Scholar : PubMed/NCBI
2.	Pienta KJ and Bradley D: Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res. 12:1665–1671. 2006. View Article : Google Scholar : PubMed/NCBI
3.	Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
4.	Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Pienta KJ and Smith DC: Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 55:300–318. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Signoretti S, Montironi R, Manola J, et al: Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst. 92:1918–1925. 2000. View Article : Google Scholar : PubMed/NCBI
7.	Scher HI and Sawyers CL: Biology of castration-resistant prostate cancer: directed therapies targeting the androgenreceptor signaling axis. J Clin Oncol. 23:8253–8261. 2005. View Article : Google Scholar : PubMed/NCBI
8.	So A, Gleave M, Hurtado-Col A and Nelson C: Mechanisms of the development of androgen independence in prostate cancer. World J Urol. 23:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
9.	Culig Z, Hobisch A, Cronauer MV, et al: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Cancer Res. 54:5474–5478. 1994.
10.	Craft N, Shostak Y, Carey M and Sawyers CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 5:280–285. 1999. View Article : Google Scholar : PubMed/NCBI
11.	Gioeli D, Ficarro SB, Kwiek JJ, et al: Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem. 277:29304–29314. 2002. View Article : Google Scholar : PubMed/NCBI
12.	Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
13.	Tolmachev V: Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des. 14:2999–3011. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Behr TM, Behe M and Wormann B: Trastuzumab and breast cancer. N Engl J Med. 345:995–996. 2001. View Article : Google Scholar : PubMed/NCBI
15.	Tolmachev V and Orlova A: Update on affibody molecules for in vivo imaging of targets for cancer therapy. Minerva Biotechnologica. 21:21–30. 2009.
16.	Nygren PA: Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J. 275:2668–2676. 2008. View Article : Google Scholar
17.	Orlova A, Magnusson M, Eriksson TL, et al: Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 66:4339–4348. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Baum RP, Prasad V, Müller D, et al: Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic ¹¹¹In- or ⁶⁸Ga-labeled Affibody molecules. J Nucl Med. 51:892–897. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Feldwisch J, Tolmachev V, Lendel C, et al: Design of an optimized scaffold for Affibody molecules. J Mol Biol. 398:232–247. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Ahlgren S, Orlova A, Wållberg H, et al: Targeting of HER2-expressing tumors using ¹¹¹In-ABY-025, a second generation Affibody molecule with a fundamentally re-engineered scaffold. J Nucl Med. 51:1131–1138. 2010.PubMed/NCBI
21.	Almqvist Y, Steffen AC, Tolmachev V, Divgi CR and Sundin A: In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer. Nucl Med Biol. 33:991–998. 2006. View Article : Google Scholar : PubMed/NCBI
22.	Wållberg H and Orlova A: Slow internalization of anti-HER2 synthetic affibody monomer ¹¹¹In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm. 23:435–442. 2008.
23.	Agus DB, Scher HI, Higgins B, et al: Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. 59:4761–4764. 1999.PubMed/NCBI
24.	Liu Y, Majumder S, McCall W, et al: Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res. 65:3404–3409. 2005.PubMed/NCBI
25.	Ziada A, Barqawi A, Glode LM, et al: The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate. 60:332–337. 2004. View Article : Google Scholar : PubMed/NCBI
26.	Lara PN Jr, Chee KG, Longmate J, et al: Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer. 100:2125–2131. 2004. View Article : Google Scholar : PubMed/NCBI
27.	Sridhar SS, Hotte SJ, Chin JL, et al: A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol. 33:609–613. 2010. View Article : Google Scholar : PubMed/NCBI
28.	Visakorpi T, Kallioniemi OP, Koivula T, Harvey J and Isola J: Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Mod Pathol. 5:643–648. 1992.PubMed/NCBI
29.	Gu K, Mes-Masson AM, Gauthier J and Saad F: Overexpression of HER-2/neu in human prostate cancer and benign hyperplasia. Cancer Lett. 99:185–189. 1996. View Article : Google Scholar : PubMed/NCBI
30.	Ahlgren S, Wållberg H, Tran TA, et al: Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med. 50:781–789. 2009. View Article : Google Scholar : PubMed/NCBI
31.	Tran TA, Rosik D, Abrahmsén L, et al: Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. Eur J Nucl Med Mol Imaging. 36:1864–1873. 2009. View Article : Google Scholar : PubMed/NCBI
32.	Austin CD, de Maziere AM, Pisacane PI, et al: Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell. 15:5268–5282. 2004. View Article : Google Scholar : PubMed/NCBI
33.	Lub-de Hooge MN, Kosterink JG, Perik PJ, et al: Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol. 143:99–106. 2004.PubMed/NCBI
34.	Orlova A, Wållberg H, Stone-Elander S and Tolmachev V: On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med. 50:417–425. 2009. View Article : Google Scholar